Acting CEO Jayden Rogers has been appointed CEO of Linear Clinical Research, Australia’s leading clinical trials facility, wholly owned by the Harry Perkins Institute of Medical Research.
Mr Rogers has been instrumental in driving Linear’s sustained growth of over 50% per annum since 2016, establishing Linear as one of the leading clinical trial sites in Asia-Pacific testing novel drugs for US, Chinese, UK and EU pharmaceutical companies.
Prior to joining Linear Mr Rogers was the Commercial Manager for OBJ Limited, an Australian listed Biotechnology company that successfully licensed its transdermal drug delivery platform with global giant Procter & Gamble.
He was a co-founder of medical device company Halo Medical Devices and has operated a range of private healthcare practices in Australia and the UK.
Mr Rogers will build on Linear’s year on year growth and guide it through a substantial expansion, doubling bed capacity in new facilities located on the QEII Medical Campus.
Linear Chair, Professor Peter Leedman, said “Under Mr Rogers’ leadership, Linear will build on its success as a world-class clinical trials facility and expand its capacity to deliver world leading early phase trials and pioneer further innovations in clinical trial delivery.”
Outgoing CEO, Dr Michael Winlo remains on the Linear Board.
